CN103341092A - Preparation method of powder for treating atrophic vaginitis - Google Patents

Preparation method of powder for treating atrophic vaginitis Download PDF

Info

Publication number
CN103341092A
CN103341092A CN2013102678096A CN201310267809A CN103341092A CN 103341092 A CN103341092 A CN 103341092A CN 2013102678096 A CN2013102678096 A CN 2013102678096A CN 201310267809 A CN201310267809 A CN 201310267809A CN 103341092 A CN103341092 A CN 103341092A
Authority
CN
China
Prior art keywords
powder
reduced pressure
atrophic vaginitis
dry extract
brown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2013102678096A
Other languages
Chinese (zh)
Other versions
CN103341092B (en
Inventor
刘晓晖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qingdao Central Hospital
Original Assignee
刘晓晖
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 刘晓晖 filed Critical 刘晓晖
Priority to CN201310267809.6A priority Critical patent/CN103341092B/en
Publication of CN103341092A publication Critical patent/CN103341092A/en
Application granted granted Critical
Publication of CN103341092B publication Critical patent/CN103341092B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

The invention discloses a preparation method of powder for treating atrophic vaginitis, aiming at solving the problem in treating atrophic vaginitis. The preparation method is characterized by comprising the following steps of: (1) carrying out reduced pressure distillation on crude powder of himalayan coralbean bark, ternate buttercup root and ephedra root and extracting volatile oil; (2) carrying out reduced pressure boiling on the volatile oil to obtain a filtrate; (3) boiling Trikeraia hookeri, Magnolia amoena, parasitic loranthus, coked malt, coked medicated leaven, spina gleditsiae, peach gum, cassia twig and the medicinal filtrate obtained in the step (1) so as to obtain a filtrate for later use; (4) combining the filtrates in the steps (2) and (3), carrying out reduced pressure concentration so as to obtain a dry extract, and crushing the dry extract to obtain dry extract powder; (5) ejecting the volatile oil obtained in the step (1) into the dry extract powder obtained in the step (4), uniformly mixing, screening in a sieve of 100 meshes and sub-packaging so as to obtain the powder. Clinical trial shows that the powder has the characteristics of being good in effect on treating atrophic vaginitis and high in security, and is worthy of clinical application and popularization.

Description

A kind of powder preparation method for the treatment of atrophic vaginitis
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to a kind of powder preparation method for the treatment of atrophic vaginitis.
Background technology
Atrophic vaginitis is a kind of nonspecific vaginitis, be common in postclimacteric elderly woman, because of the ovarian function decline, the a lot of levels of estrogen reduce vaginal wall atrophy, mucosa attenuation, glycogen content reduces in the epithelial cell, intravaginal Ph value rises, and local resistance reduces, and pathogenic bacterium are invaded breeding easily and cause and inflammation.Cardinal symptom is that vaginal secretions increases and pruritus vulvae, burning sensation.Inspection sees that vagina is senile change, last atrophoderma, and pleat disappears, and it is sliding, poor that epithelium flattens.Vaginal mucosa hyperemia has little petechia, sees shallow table ulcer sometimes.
The Therapeutic Principle is for increasing the growth and breeding of vagina resistance and inhibition antibacterial.Present western medical treatment mostly is and replenishes a small amount of estrogen, and vaginal mucosa is thickened, and builds up resistance.But estrogenic unreasonable use easily causes carcinoma of endometrium and breast carcinoma, so there is dispute in this kind therapeutic scheme always.Bacteria growing inhibiting is then for to put into the antibiotic powder in intravaginal, but life-time service can cause local dysbacteriosis, causes bigger puzzlement.
And the colpitic suppository of Chinese traditional treatment, outer lotion are many, but be mostly at the child-bearing period women, contain Radix Sophorae Flavescentis, Fructus Cnidii, the Fructus Kochiae, Rhizoma Smilacis Glabrae etc. in the prescription except the medicine of noxious dampness more, and mainly being the mucosa attenuation, the cause of atrophic vaginitis causes, the medicine external of above dispelling the damp pathogen with drugs of bitter in taste and cold in nature, then irritates nucous membrane more causes the state of an illness to increase the weight of.
Summary of the invention
Technical assignment of the present invention is at above the deficiencies in the prior art, provides a kind of curative effect certainly and the powder of the treatment atrophic vaginitis that side effect is little.
The technical scheme that the present invention solves its technical problem is: a kind of powder for the treatment of atrophic vaginitis is characterized in that being prepared from by following materials of weight proportions medicine: 10 ~ 30 parts of Cortex erythrinaes, 6 ~ 12 parts of Herba Chlorophyti Laxis, go back 3 ~ 10 parts in bobbin, 6 ~ 12 parts of Flos Magnoliae Amoenae, 3 ~ 10 parts of Herba Taxillis, 6 ~ 12 parts of Radix Ranunculi Ternatis, 6 ~ 12 parts of Fructus Hordei Germinatus (parched to brown)s, 6 ~ 12 parts of Massa Medicata Fermentata (parched to brown), 6 ~ 12 parts of Radix Ephedraes, 1 ~ 5 part of Spina Gleditsiae, 3 ~ 10 parts of gumshiraz, 10 ~ 25 parts of Ramulus Cinnamomi.
Chinese medicine of the present invention can be prepared from by following method:
(1) volatile oil is extracted in Cortex erythrinae, Radix Ranunculi Ternati, the distilling under reduced pressure of Radix Ephedrae coarse powder difference, and collect back mixing for standby use, medicinal residues mixing for standby use;
(2) will go back the bobbin decompression and decoct 2 times, each 30min, collecting decoction leaves standstill the back and filters, and gets filtrate for later use;
(3) gained medicinal residues in Herba Chlorophyti Laxi, Flos Magnoliae Amoenae, Herba Taxilli, Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown), Spina Gleditsiae, gumshiraz, Ramulus Cinnamomi and the step 1 are added 10 times of water yields, decoct with water 2 times, each 1 hour, collecting decoction left standstill the back and filters, and gets filtrate for later use;
(4) step 2 gained filtrate and step 3 gained filtrate are merged, concentrating under reduced pressure becomes dry extract, pulverize dry extract;
(5) gained volatile oil in the step 1 is sprayed in the step 4 gained dry extract, mixing is crossed 100 mesh sieves, and packing forms.
The pressure of the distilling under reduced pressure in the above-mentioned steps (1) is 0.1Mpa.
The pressure that decompression in the above-mentioned steps (2) decocts is 0.4Mpa.
The pressure of the concentrating under reduced pressure in the above-mentioned steps (4) is 0.4Mpa.
Wherein said: Cortex erythrinae is bark or the root bark of pulse family Erythrinae Arborescentis Erythrina indica Lam..The nature and flavor hardship, flat.Return liver, kidney channel.But the merit wind-damp dispelling, channels sootheing and network vessel quickening.Wind-damp dispelling, the meridian dredging, parasite killing.
Herba Chlorophyti Laxi is herb or the root of feverfew Prenanthes henryi Dunn Prenanthes henryi Dunn.Bitter in the mouth; Cold in nature.But merit heat-clearing and toxic substances removing; The dissipating blood stasis hemostasis.
Also bobbin is the fruit of orchid Rhizoma Gastrodiae Gastrodia elata Bl..Sweet in the mouth; Cold in nature.But merit tonify deficiency subduing the wind syndrome.Main dizzy; Pupil; The wind syndrome of head headache; The weak breath consumption of essence; Early whitening of beard and hair.
Flos Magnoliae Amoenae for Magnoliaceae head Drymotaenium miyoshianum (Mak.) Mak. Magnolia amoena Cheng, is used as medicine with alabastrum.The nature and flavor hardship, cold.But the merit diuresis, detumescence, nourishing the lung to arrest cough.
Herba Taxilli is the dry stem and branch with leaf of Loranthaceae plant Herba Taxilli Taxillus chinensis (DC.) Danser for Herba Taxilli.Nature and flavor hardship, sweet, flat.Return liver, kidney channel.But the merit invigorating the liver and kidney, bone and muscle strengthening, wind-damp dispelling, antiabortive unit.
Radix Ranunculi Ternati is the dried root of the little Herba Ranunculi Japonici Ranunculus of ranunculaceae plant ternatus Thunb..Nature and flavor are sweet, hot, temperature.Return liver, lung meridian.But the merit eliminating stagnation, detumescence.
Fructus Hordei Germinatus (parched to brown), for the mature fruit of grass Fructus Hordei Vulgaris Hordeum vulgare L. through the drying of germinateing, fry to burnt brown according to the method for frying, cool sieve dedust bits.Nature and flavor are sweet, and are flat.Return spleen, stomach warp.But the merit promote qi circulation digestion promoting, spleen benefiting and stimulating the appetite moves back newborn relieving distension.
Massa Medicata Fermentata (parched to brown), for medicines such as Herba polygoni hydropiperis, Herba Artemisiae Annuae, Semen Armeniacae Amarum add flour or wheat bran mixed after, through the herbal leaven that fermentation forms, fry to burnt brown according to frying method.The sweet suffering of nature and flavor, temperature.Go into spleen, stomach warp.But the merit invigorating the spleen and regulating the stomach is in the accent that helps digestion.
Radix Ephedrae is the dry root and rhizome of Ephedraceae plant plait Herba Ephedrae Ephedra sinica Stapf or epheday intermedia Ephedra intermedia Schrenk et C. A. Mey..Nature and flavor are sweet, and are flat.GUIXIN, lung meridian.But merit hidroschesis.
Spina Gleditsiae is the dry Spina jujubae of leguminous plant Fructus Gleditsia Gleditsia sinensis Lam..The nature and flavor suffering, temperature.Return liver, stomach warp.The merit poison holding of can subsiding a swelling, evacuation of pus, parasite killing.
Gumshiraz is rosaceous plant peach Prunus persica (L.) Batsch, the resin that flows out on the trunk.Nature and flavor hardship, flat.Merit can be invigorated blood circulation, and QI invigorating is quenched the thirst.
Ramulus Cinnamomi is the dry twig of canella Cortex Cinnamomi Cinnamomum cassia Presl.Nature and flavor suffering, sweet, temperature.GUIXIN, lung, urinary bladder channel.But merit diaphoresis expelling pathogenic factors from muscles, promoting the flow of QI-blood by warming the meridian, supporing yang activating QI, the flat gas that spins.
Composition principle: atrophic vaginitis is common in postclimacteric elderly woman, because of the ovarian function decline, the a lot of levels of estrogen reduce, the vaginal wall atrophy, glycogen content reduces in the mucosa attenuation, epithelial cell, and intravaginal Ph value rises, local resistance reduces, and pathogenic bacterium are invaded breeding easily and cause and inflammation.Cardinal symptom is that vaginal secretions increases and pruritus vulvae, burning sensation.At present the colpitic suppository of Chinese traditional treatment, outer lotion are many, but be mostly at the child-bearing period women, contain Radix Sophorae Flavescentis, Fructus Cnidii, the Fructus Kochiae, Rhizoma Smilacis Glabrae etc. in the prescription except the medicine of noxious dampness more, and mainly being the mucosa attenuation, the cause of atrophic vaginitis causes, the medicine external of above dispelling the damp pathogen with drugs of bitter in taste and cold in nature, then irritates nucous membrane more causes the state of an illness to increase the weight of.The objective of the invention is to avoid using the dispelling the damp pathogen with drugs of bitter in taste and cold in nature medicine, and reduce from estrogen level, the vaginal wall atrophy, this pathological change angle of mucosa attenuation is started with, and reaches the purpose of " treatment of disease must aim at its pathogenesis ".
Compared with prior art, the present invention has following characteristics:
1, prescription uniqueness, avoid using the dispelling the damp pathogen with drugs of bitter in taste and cold in nature antipruritic agent: get Cortex erythrinae in the side, go back bobbin and be monarch, Cortex erythrinae dosage of record is in " China's book on Chinese herbal medicine ": " taking orally: fry in shallow oil soup, 6-12g "; (10 ~ 30g) can recover by specific promotion vaginal wall mucosa heavy dose of Cortex erythrinae during the inventor experimental results show that, and go back bobbin the similar plants estrogen action is arranged, but this act as two-ways regulation, can not produce the low differentiation of the excessive stimulation reproductive system of estrogen cell;
2, characteristic of the present invention also is balance and restriction: record Cortex erythrinae in 1. " must joining book on Chinese herbal medicine ": " insufficiency of blood heated person forbidding ", but the gerontal patient is often with the resembling of deficiency of YIN-blood, and use Cortex erythrinae this moment then has its hematozemia of fearing and causes the yin asthenia generating intrinsic heat appearance; So add Herba Chlorophyti Laxi and go back bobbin, also but the training of bobbin merit tonify deficiency is basic, and can prevent that Cortex erythrinae from consuming cloudy blood and liver-wind stirring up internally, and the Herba Chlorophyti Laxi bitter in the mouth is cold in nature, utilize its cold heated that prevents on the one hand, but its merit dissipating blood stasis hemostasis on the other hand there is out entire merit in blood system, prevent the Cortex erythrinae moving blood of wandering away, also can not influence Cortex erythrinae simultaneously and work orderly effect; 2. the use of Ramulus Cinnamomi is among the we: a promoting the flow of QI-blood by warming the meridian, and supporing yang activating QI, two Yin Yang balancings are with the bitter cold of balance we invasion by pathogenic cold medicine of a cold nature thing; The application characteristic of Ramulus Cinnamomi is in the prescription of the present invention: measure that bigger (" consumption in the Chinese pharmacopoeia is 3 ~ 9g), so too disperse for preventing, gets Radix Ephedrae convergence assistant system again;
3, the supplementary drug thing is fewer but better: get the Flos Magnoliae Amoenae assistant in the side and help Herba Chlorophyti Laxi, heat conduction is descending; Radix Ranunculi Ternati and Herba Chlorophyti Laxi collocation have the effect of detoxifcation, eliminating stagnation, pain relieving; The Herba Taxilli assistant helps goes back the bobbin vital base and primordial QI consolidating; Gumshiraz is invigorated blood circulation, and helps medicine to stay in mucomembranous surface, promotes to absorb;
4, inventor's clinical research is found, helps the control of the atrophic vaginitis course of disease and recovery admittedly protect gastric qi, so select Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown) spleen benefiting and stimulating the appetite for use;
5, Spina Gleditsiae is the supplementary drug thing, in " China book on Chinese herbal medicine " record consumption be: " for oral administration: as to fry in shallow oil soup, 6 ~ 12g ", inventor's experimental study are found, get low dose of Spina Gleditsiae decocting liquid and can improve the vaginal mucosa cytoactive that exsomatizes;
6, the thing homogeneous medicine multiple-effect of getting it filled in the side helps to reduce medicament categories and consumption, does not increase local excitation;
7, medicine material consumption of the present invention is groped to sum up to draw through the inventor in a large number, and each raw material consumption is for all to have curative effect preferably in the following weight parts scope;
8, go back the fruit that bobbin is the orchid Rhizoma Gastrodiae, comparing with Rhizoma Gastrodiae, go back the esterification enzyme isoenzyme (esterase isoenzyme) that bobbin contains, may be the key of its performance phytoestrogen effect, and inventor's experiment draws, and it is higher to go back bobbin esterification enzyme isoenzyme content after decompression decocts.
The specific embodiment
Below in conjunction with practical situation, the specific embodiment of the present invention is elaborated.
Embodiment 1, the crude drug weight proportion: Cortex erythrinae 20g, Herba Chlorophyti Laxi 10g, go back bobbin 6g, Flos Magnoliae Amoenae 10g, Herba Taxilli 6g, Radix Ranunculi Ternati 10g, Fructus Hordei Germinatus (parched to brown) 10g, Massa Medicata Fermentata (parched to brown) 10g, Radix Ephedrae 10g, Spina Gleditsiae 2g, gumshiraz 6g, Ramulus Cinnamomi 20g.
The preparation method of embodiment 1 is: with Cortex erythrinae, Herba Chlorophyti Laxi, go back bobbin, Flos Magnoliae Amoenae, Herba Taxilli, Radix Ranunculi Ternati, Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown), Radix Ephedrae, Spina Gleditsiae, gumshiraz, Ramulus Cinnamomi mixing and water adding and decoct, get filtrate after 30 minutes, medicinal residues add water continuation decoction and get filtrate after 20 minutes, twice filtrate merges washout, once a day.
Embodiment 2, the crude drug weight proportion: 10 parts of Cortex erythrinaes, 6 parts of Herba Chlorophyti Laxis, go back 3 parts in bobbin, 6 parts of Flos Magnoliae Amoenae, 3 parts of Herba Taxillis, 6 parts of Radix Ranunculi Ternatis, 6 parts of Fructus Hordei Germinatus (parched to brown)s, 6 parts of Massa Medicata Fermentata (parched to brown), 6 parts of Radix Ephedraes, 1 part of Spina Gleditsiae, 3 parts of gumshiraz, 10 parts of Ramulus Cinnamomi.
Embodiment 3, the crude drug weight proportion: 20 parts of Cortex erythrinaes, 10 parts of Herba Chlorophyti Laxis, go back 6 parts in bobbin, 10 parts of Flos Magnoliae Amoenae, 6 parts of Herba Taxillis, 10 parts of Radix Ranunculi Ternatis, 10 parts of Fructus Hordei Germinatus (parched to brown)s, 10 parts of Massa Medicata Fermentata (parched to brown), 10 parts of Radix Ephedraes, 2 parts of Spina Gleditsiaes, 6 parts of gumshiraz, 20 parts of Ramulus Cinnamomi.
Embodiment 4, the crude drug weight proportion: 30 parts of Cortex erythrinaes, 12 parts of Herba Chlorophyti Laxis, go back 10 parts in bobbin, 12 parts of Flos Magnoliae Amoenae, 10 parts of Herba Taxillis, 12 parts of Radix Ranunculi Ternatis, 12 parts of Fructus Hordei Germinatus (parched to brown)s, 12 parts of Massa Medicata Fermentata (parched to brown), 12 parts of Radix Ephedraes, 5 parts of Spina Gleditsiaes, 10 parts of gumshiraz, 25 parts of Ramulus Cinnamomi.
The Chinese medicine of embodiment 2 ~ 4 can be prepared from by following method:
(1) volatile oil is extracted in Cortex erythrinae, Radix Ranunculi Ternati, the distilling under reduced pressure of Radix Ephedrae coarse powder difference, and collect back mixing for standby use, medicinal residues mixing for standby use;
(2) will go back the bobbin decompression and decoct 2 times, each 30min, collecting decoction leaves standstill the back and filters, and gets filtrate for later use;
(3) gained medicinal residues in Herba Chlorophyti Laxi, Flos Magnoliae Amoenae, Herba Taxilli, Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown), Spina Gleditsiae, gumshiraz, Ramulus Cinnamomi and the step 1 are added 10 times of water yields, decoct with water 2 times, each 1 hour, collecting decoction left standstill the back and filters, and gets filtrate for later use;
(4) step 2 gained filtrate and step 3 gained filtrate are merged, concentrating under reduced pressure becomes dry extract, pulverize dry extract;
(5) gained volatile oil in the step 1 is sprayed in the step 4 gained dry extract, mixing is crossed 100 mesh sieves, and packing forms.
In the prioritization scheme, the pressure of the distilling under reduced pressure in the described step (1) is 0.1Mpa; The pressure that decompression in the described step (2) decocts is 0.4Mpa; The pressure of the concentrating under reduced pressure in the described step (4) is 0.4Mpa.
Effective combination of said medicine is coordinated mutually, effectively reach the purpose for the treatment of atrophic vaginitis, and side effect is less.The above results is that clinical data proves that fully interrelated data is as follows.
1 object and method.
1.1 object.
1 data and method.
1.1.1 case is selected: in February, 2011 ~ 2013 are diagnosed as atrophic vaginitis 160 examples year June, 49 years old~69 years old age, be menopausal women, and be limited to 1 year menopause ~ 20 years.
1.1.2 diagnostic criteria: with reference to " obstetrics and gynecology " (the 5th edition), all case is all clarified a diagnosis according to medical history, gynecologial examination.Symptom is xerosis vulae, the pale or flushing of vaginal mucosa or little petechia is arranged, vaginal health scoring<15 minutes, serum follicle stimulating hormone (FSH) 〉=40IU/L, serum estradiol (E2)≤110pmol/L, abdominal ultrasound examination endometrium thickness<5mm.All patients all carry out the vaginal secretions inspection and get rid of trichomonal vaginitis, monilial vaginitis before treatment, urine is cultivated negative, no vulvar dystrophy and dermatosis.All cases are got rid of hormone-dependent tumor, do not accept the hormone medicine treatment over nearly 3 months.
1.1.3 grouping: be divided into matched group 53 examples, washout group 53 example and powder group 54 examples.Compare in age, the state of an illness, the course of disease before three groups of patient treatments, and the difference not statistically significant (P〉0.05), have comparability.
1.2 method.
1.2.1 Therapeutic Method: matched group adopts 1% lactic acid solution washout, the red and swollen significantly local use antibiotic Emulsion of pudendum, 1 time/d.The washout group is with gained decoct washout in the embodiment of the invention 1,1 time/d.The powder group is blown deposited with gained powder pudendum and intravaginal in the embodiment of the invention 3,1 time/d.14 days is a course for the treatment of.
1.2.2 observation index: conventional inquiry medical history before and after the medication, and according to vaginal health point system (VHS) scoring, determine the doing well,improving situation.
1.2.3 criterion of therapeutical effect: with reference to " obstetrics and gynecology ", recovery from illness: clinical symptoms, sign disappear; Produce effects: clinical symptoms, sign turn for the better by and large; Effectively: clinical symptoms, sign alleviate; Invalid: clinical symptoms, sign no change.
1.2.4 statistical analysis: SPSS 13.0 carries out statistical analysis.Vaginal health scoring single index adopts nonparametric statistics.Measurement data is checked with t, enumeration data χ 2Check.
2 results
2.1 vaginal symptoms is improved situation: behind the medication 5d, matched group 69.81%(37/51) patient, and washout group and all case vagina drying of powder group, dyspareunia symptom all begin to obtain improvement in various degree.Gynecologial examination vaginal wall elasticity increases, and fold is deepened, and the surface is pale, flushing and bleeding are clearly better.According to the vaginal health standards of grading, the vaginal health scoring is the summation of elasticity, wettability, pH, mucosa, 5 project score values of secretions.Scoring is 8.27 ± 1.74 before the washout group patient medication, and the scoring average is 14.26 ± 1.93 behind the medication 14d.Scoring is 9.15 ± 2.62 before the powder group patient medication, and the scoring average is 17.53 ± 2.62 behind the medication 14d.Relatively, (P<0.05) is all obviously increased in the vaginal health scoring behind two groups of patient treatments before and after the medication.
2.2 three groups of clinical comprehensive therapeutic effects relatively: behind the medication 14d, matched group cure rate, obvious effective rate, effective percentage, inefficiency are respectively 20.75%, 35.85%, 35.85%, 7.55%; The cure rate of washout group, obvious effective rate, effective percentage, inefficiency are respectively 56.60%, 33.96%, 9.43%, 0.00%; The cure rate of powder group, obvious effective rate, effective percentage, inefficiency are respectively 70.37%, 18.52%, 11.11%, 0.00%.Three groups relatively, and the cure rate of washout group and powder group, total effective rate are apparently higher than matched group (P<0.05), and the cure rate of powder group is apparently higher than washout group (P<0.05).
2.3 adverse reaction rate: obvious adverse reaction does not all appear in three groups of patients.
2.4 relapse rate: in 3 months, matched group has 11.32%(6/53) case appearance recurrence, washout group relapse rate is 3.77%(2/53), the powder group is 1.85%(1/54).
3. conclusion.
This result of study shows that washout group of the present invention and powder group treatment atrophic vaginitis total effective rate are 100%, and the cure rate of powder group is higher than the washout group.Have that untoward reaction is light, the safety advantage of higher.And relapse rate is low in 3 months.

Claims (4)

1. preparation method for the treatment of atrophic vaginitis powder, it is characterized in that, crude drug comprises: Cortex erythrinae, Herba Chlorophyti Laxi, go back bobbin, Flos Magnoliae Amoenae, Herba Taxilli, Radix Ranunculi Ternati, Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown), Radix Ephedrae, Spina Gleditsiae, gumshiraz, Ramulus Cinnamomi, its preparation method is made up of following steps:
(1) volatile oil is extracted in Cortex erythrinae, Radix Ranunculi Ternati, the distilling under reduced pressure of Radix Ephedrae coarse powder difference, and collect back mixing for standby use, medicinal residues mixing for standby use;
(2) will go back the bobbin decompression and decoct 2 times, each 30min, collecting decoction leaves standstill the back and filters, and gets filtrate for later use;
(3) gained medicinal residues in Herba Chlorophyti Laxi, Flos Magnoliae Amoenae, Herba Taxilli, Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown), Spina Gleditsiae, gumshiraz, Ramulus Cinnamomi and the step 1 are added 10 times of water yields, decoct with water 2 times, each 1 hour, collecting decoction left standstill the back and filters, and gets filtrate for later use;
(4) step 2 gained filtrate and step 3 gained filtrate are merged, concentrating under reduced pressure becomes dry extract, pulverize dry extract;
(5) gained volatile oil in the step 1 is sprayed in the step 4 gained dry extract, mixing is crossed 100 mesh sieves, and packing forms.
2. a kind of preparation method for the treatment of atrophic vaginitis powder according to claim 1, it is characterized in that: the pressure of the distilling under reduced pressure in the described step (1) is 0.1Mpa.
3. a kind of preparation method for the treatment of atrophic vaginitis powder according to claim 1 is characterized in that: the pressure that the decompression in the described step (2) decocts is 0.4Mpa.
4. a kind of preparation method for the treatment of atrophic vaginitis powder according to claim 1, it is characterized in that: the pressure of the concentrating under reduced pressure in the described step (4) is 0.4Mpa.
CN201310267809.6A 2013-07-01 2013-07-01 Preparation method of powder for treating atrophic vaginitis Expired - Fee Related CN103341092B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310267809.6A CN103341092B (en) 2013-07-01 2013-07-01 Preparation method of powder for treating atrophic vaginitis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510279340.7A CN104815243A (en) 2013-07-01 2013-07-01 Preparation method of external washing liquid for atrophic vaginitis
CN201310267809.6A CN103341092B (en) 2013-07-01 2013-07-01 Preparation method of powder for treating atrophic vaginitis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510279340.7A Division CN104815243A (en) 2013-07-01 2013-07-01 Preparation method of external washing liquid for atrophic vaginitis

Publications (2)

Publication Number Publication Date
CN103341092A true CN103341092A (en) 2013-10-09
CN103341092B CN103341092B (en) 2015-07-15

Family

ID=49275952

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201310267809.6A Expired - Fee Related CN103341092B (en) 2013-07-01 2013-07-01 Preparation method of powder for treating atrophic vaginitis
CN201510279340.7A Pending CN104815243A (en) 2013-07-01 2013-07-01 Preparation method of external washing liquid for atrophic vaginitis

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510279340.7A Pending CN104815243A (en) 2013-07-01 2013-07-01 Preparation method of external washing liquid for atrophic vaginitis

Country Status (1)

Country Link
CN (2) CN103341092B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103316258A (en) * 2013-07-01 2013-09-25 王莉莉 Medicine composition for treating infantile vaginitis
CN103316269A (en) * 2013-07-01 2013-09-25 付海霞 Medicine composition for treating primary enuresis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1530126A (en) * 2003-03-13 2004-09-22 哈尔滨欧替药业股份有限公司 Medicine composition, preparing method and use for preparing gynacecopathia medicine
CN102727779A (en) * 2012-07-04 2012-10-17 王海霞 Pharmaceutical composition for treating ovarian cysts and preparation method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1304038C (en) * 2005-04-12 2007-03-14 北京荔博园医药研究所 Medicinal composition for treating elytritis, preparation and its quality control method
CN102145064B (en) * 2011-04-18 2012-09-26 李佃场 Traditional Chinese medicine composition for treating senile vaginitis and preparation method thereof
CN103071096B (en) * 2013-01-30 2014-07-23 李秀娟 External preparation for treating senile vaginitis and preparation method of external preparation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1530126A (en) * 2003-03-13 2004-09-22 哈尔滨欧替药业股份有限公司 Medicine composition, preparing method and use for preparing gynacecopathia medicine
CN102727779A (en) * 2012-07-04 2012-10-17 王海霞 Pharmaceutical composition for treating ovarian cysts and preparation method thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
张亚平: "阴痒验案二则", 《吉林中医药》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103316258A (en) * 2013-07-01 2013-09-25 王莉莉 Medicine composition for treating infantile vaginitis
CN103316269A (en) * 2013-07-01 2013-09-25 付海霞 Medicine composition for treating primary enuresis

Also Published As

Publication number Publication date
CN103341092B (en) 2015-07-15
CN104815243A (en) 2015-08-05

Similar Documents

Publication Publication Date Title
CN101711848B (en) Chinese medicinal composition capable of adjunctively treating tumour
CN103041262B (en) Traditional Chinese medicine enema for curing chronic prostatitis and preparing method thereof
CN103301353B (en) Pharmaceutical composition for treating atrophic vaginitis
CN103285284B (en) Medical composition for treating senile vaginitis
CN103356932B (en) A kind of pharmaceutical composition for the treatment of vulva squamous epithelial hyperplasia
CN105233188A (en) Traditional Chinese medicine composition for treating liver cancer and application of traditional Chinese medicine composition
CN103341092B (en) Preparation method of powder for treating atrophic vaginitis
CN103330867B (en) Preparation method of powder for treating senile vaginitis
CN103301373B (en) Pharmaceutical composition for treating postpartum perineal mucosal lesions
CN104887950A (en) Mastitis treatment traditional Chinese medicine compound
CN104998197A (en) Traditional Chinese medicine composition for treating liver cancer
CN103330896B (en) Preparation method of powder for treating postpartum nonspecific vaginitis
CN103301374B (en) Pharmaceutical composition for treating postpartum non-specificity vaginitis
CN103341094B (en) Preparation method of powder for treating vulva squamous epithelial cell hyperplasia
CN103316270B (en) Preparation method of powder of medicine for treating postnatal perineum mucosal lesion
CN103285300A (en) Medicinal composition for treating stress incontinence
CN105250749A (en) Traditional Chinese medicine for treating thyroid adenoma and preparation method thereof
CN104524149A (en) Pharmaceutical composition for preventing and treating acute nephritis and application thereof
CN103301354B (en) Preparation method of powder for treating infantile vaginitis
CN103316258B (en) Medicine composition for treating infantile vaginitis
CN103006957A (en) Pharmaceutical composition for preventing and treating osteoporosis and preparation method thereof
CN112717113A (en) Traditional Chinese medicine composition for treating allergic rhinitis and ointment formula and application thereof
CN106237261A (en) A kind of for decoction medicine treating gastric cancer and preparation method thereof
CN101167915B (en) Traditional Chinese medicine for treating chronic superficial gastritis and its preparation method
CN105362617A (en) Medicine for treating chronic urinary retention and preparation method of medicine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
C53 Correction of patent for invention or patent application
ASS Succession or assignment of patent right

Owner name: ZHONGXIN HOSPITAL, QINGDAO

Free format text: FORMER OWNER: LIU XIAOHUI

Effective date: 20150616

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: LIU XIAOHUI TO: SUN HONGQIAO CONG MINGHUI ZHANG XINYI GONG ZHIHUA

CB03 Change of inventor or designer information

Inventor after: Sun Hongqiao

Inventor after: Cong Minghui

Inventor after: Zhang Xinyi

Inventor after: Gong Zhihua

Inventor before: Liu Xiaohui

TA01 Transfer of patent application right

Effective date of registration: 20150616

Address after: 127 Qingdao Central Hospital, four South Stream Road, Shandong, Qingdao 266042, China

Applicant after: Zhongxin Hospital, Qingdao

Address before: 257034 Central Hospital of Shengli Oil Field, 280 Ji'nan Road, Dongying, Shandong, Xicheng District

Applicant before: Liu Xiaohui

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150715

Termination date: 20170701

CF01 Termination of patent right due to non-payment of annual fee